ATE349523T1 - Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten - Google Patents

Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Info

Publication number
ATE349523T1
ATE349523T1 AT01977082T AT01977082T ATE349523T1 AT E349523 T1 ATE349523 T1 AT E349523T1 AT 01977082 T AT01977082 T AT 01977082T AT 01977082 T AT01977082 T AT 01977082T AT E349523 T1 ATE349523 T1 AT E349523T1
Authority
AT
Austria
Prior art keywords
human
related polypeptide
treat diseases
diseases
immunodeficiencies
Prior art date
Application number
AT01977082T
Other languages
English (en)
Inventor
Andrew Lawrence Glasebrook
Ling Liu
Christy Michelle Newton
Jonathan Wendell Tetreault
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26933217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE349523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE349523T1 publication Critical patent/ATE349523T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01977082T 2000-10-13 2001-09-28 Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten ATE349523T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24017700P 2000-10-13 2000-10-13
US30993601P 2001-08-03 2001-08-03

Publications (1)

Publication Number Publication Date
ATE349523T1 true ATE349523T1 (de) 2007-01-15

Family

ID=26933217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01977082T ATE349523T1 (de) 2000-10-13 2001-09-28 Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Country Status (7)

Country Link
US (1) US20060083713A1 (de)
EP (1) EP1326974B1 (de)
AT (1) ATE349523T1 (de)
AU (1) AU2001296229A1 (de)
DE (1) DE60125563T2 (de)
ES (1) ES2277947T3 (de)
WO (1) WO2002033083A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
EP3112468A1 (de) * 1998-05-15 2017-01-04 Genentech, Inc. Il-17-homologe polypeptide und therapeutische verwendung davon
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60125563T2 (de) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
MXPA05000655A (es) * 2002-07-15 2006-02-22 Harvard College Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th).
ES2751414T5 (es) 2003-07-08 2024-04-23 Novartis Pharma Ag Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
EP1671642A1 (de) 2004-12-15 2006-06-21 Universite D'angers Zusammensetzungen mit (Ant)agonisten von Oncostatin M (OSM), IL-31 und IFN-gamma zur Modulierung der Migration und Funktion von Keratinozyten via einen Rezeptor welcher OSMRbeta als Untereinheit enthält, und entprechende Anwendungen
CN101784269A (zh) * 2007-06-26 2010-07-21 莱西肯医药有限公司 治疗由5-羟色胺介导的疾病和病症的方法
SG10201608871XA (en) 2008-05-05 2016-12-29 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2010133662A1 (en) * 2009-05-20 2010-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-17 polypeptides for use in the prevention or treatment of atherosclerosis
US20130064788A1 (en) * 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
US11135268B2 (en) * 2015-07-07 2021-10-05 Fred Hutchinson Cancer Research Center Compositions, kits, and methods using interleukin-17C to promote neural growth and/or neural survival
CA3023451A1 (en) 2016-05-06 2017-11-09 Exicure, Inc. Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
CN106153923B (zh) * 2016-06-21 2017-12-05 北京大学第一医院 预测谷丙转氨酶小于二倍正常上限的慢性乙型病毒性肝炎患者肝脏炎症程度的系统
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138930A0 (en) * 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
WO1999061617A1 (en) * 1998-05-29 1999-12-02 Human Genome Sciences, Inc. Interleukins-21 and 22
WO2000020593A1 (en) * 1998-10-02 2000-04-13 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and uses thereof
PT1240325E (pt) * 1999-12-23 2010-01-07 Genentech Inc Polipéptidos homólogos de il-17 e il-17r e suas utilizações terapêuticas
AU784727B2 (en) * 2000-02-08 2006-06-01 Amgen, Inc. IL-17 like molecules and uses thereof
JP2004504064A (ja) * 2000-06-22 2004-02-12 アムジエン・インコーポレーテツド Ｉｌ−１７分子およびその用途
AU7303301A (en) * 2000-07-27 2002-02-13 Ludwig Inst Cancer Res Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
DE60125563T2 (de) * 2000-10-13 2007-10-04 Eli Lilly And Co., Indianapolis Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten

Also Published As

Publication number Publication date
WO2002033083A3 (en) 2003-03-06
EP1326974A2 (de) 2003-07-16
DE60125563D1 (de) 2007-02-08
ES2277947T3 (es) 2007-08-01
WO2002033083A2 (en) 2002-04-25
DE60125563T2 (de) 2007-10-04
US20060083713A1 (en) 2006-04-20
AU2001296229A1 (en) 2002-04-29
EP1326974B1 (de) 2006-12-27

Similar Documents

Publication Publication Date Title
ATE349523T1 (de) Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
NO2016007I2 (no) Susoktokog
DE69827651D1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
EA200200755A1 (ru) Опосредованная рецептором nogo блокада роста аксонов
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
ATE421329T1 (de) Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
ATE180277T1 (de) Zur behandlung von tumoren und hiv-infektionen nützliches pflanzliches protein
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE397085T1 (de) Verfahren zur reproduzierung von pleuromutilinen
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
EA199900006A1 (ru) Препарат и способ для лечения застоной сердечной недостаточности
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties